Swiss Pharma Novartis to Invest Billion Dollars in China

Swiss pharmaceutical group Novartis said Tuesday that it would invest 1.0 billion dollars (680 million euros) in research and development in China to latch on to growing demand for

Swiss pharmaceutical group Novartis said Tuesday that it would invest 1.0 billion dollars (680 million euros) in research and development in China to latch on to growing demand for health care.

The five-year investment will include an expansion of the company's Institute for BioMedical Research in Shanghai (CNIBR) which specialises in basic research and developing new drugs, Novartis said in a statement.

Novartis To Insert Microchips In Pills To Remind Patients
Novartis will be inserting tiny microchips into blood pressure pills to track whether patients are taking their meds as prescribed. When patients veer off course, they get a text message reminder.

"We are confident that our expanded investment in R&D will result in innovative therapies for patients in China and other countries nurtured by the growing scientific excellence in China," said chief executive Daniel Vasella.

The institute is to become the third largest research facility for the group after centres at its headquarters in the Swiss city of Basel and in the United States, employing about 1,000 researchers instead of the current 160.

Another 250 million dollars will go to a new global technical centre which is opening in Changshu.

Novartis Plans Big on MS Drugs
Swiss giant Novartis is planning big on multiple sclerosis (MS) drugs. It has already received FDA nod for selling Extavia, a copy of Bayer’s own MS drug Betaseron.

Novartis said the demand for health care in China was growing rapidly, as the population suffered from a greater burden of chronic diseases associated with lifestyle choices.

The Chinese government has announced a 124-billion-dollar plan to expand access to affordable health care over the next three years, it added.

Novartis Ships Seasonal Flu Vaccine Ahead of Schedule to US
Swiss drug-maker Novartis said Wednesday that it had begun shipping seasonal flu vaccine to the United States weeks ahead of schedule, in order to address increased demand amid the swine flu pandemic.

Source-AFP
SRM

Research on MRSA Drug Halted by Novartis After Poor Tests
Novartis said Friday it was halting research into its Aurograb treatment designed to combat bacterial infections such as the deadly MRSA bug after disappointing clinical tests.